Taku Okazaki

Taku Okazaki

Auto-generated profile, based on publicly available information

Taku Okazaki

Laboratory of Molecular Immunology, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2000 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GFGordon J. Freeman
Gordon J. Freeman
ALAndrew J. Long
Andrew J. Long
YIYoshiko Iwai
Yoshiko Iwai
KBKaren Bourque
Karen Bourque
TCTatyana Chernova
Tatyana Chernova
THTasuku Honjo
Tasuku Honjo
PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells. Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features. We report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family. Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. In addition, PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation. PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ, and activated human and murine dendritic cells. In addition, PD-L1 is expressed in nonlymphoid tissues such as heart and lung. The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may determine the extent of T cell activation and consequently the threshold between tolerance and autoimmunity. PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently determine the extent of immune responses at sites of inflammation.

6 September 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YIYoshiko Iwai
Yoshiko Iwai
MIMasayoshi Ishida
Masayoshi Ishida
Yoshimasa TanakaYoshimasa Tanaka
Yoshimasa Tanaka
TOTaku Okazaki
Taku Okazaki
THTasuku Honjo
Tasuku Honjo
NMNagahiro Minato
Nagahiro Minato
PD-1 is a receptor of the Ig superfamily that negatively regulates T cell antigen receptor signaling by interacting with the specific ligands (PD-L) and is suggested to play a role in the maintenance of self-tolerance. In the present study, we examined possible roles of the PD-1/PD-L system in tumor immunity. Transgenic expression of PD-L1, one of the PD-L, in P815 tumor cells rendered them less susceptible to the specific T cell antigen receptor-mediated lysis by cytotoxic T cellsin vitro, and markedly enhanced their tumorigenesis and invasivenessin vivoin the syngeneic hosts as compared with the parental tumor cells that lacked endogenous PD-L. Both effects could be reversed by anti-PD-L1 Ab. Survey of murine tumor lines revealed that all of the myeloma cell lines examined naturally expressed PD-L1. Growth of the myeloma cells in normal syngeneic mice was inhibited significantly albeit transiently by the administration of anti-PD-L1 Abin vivoand was suppressed completely in the syngeneic PD-1-deficient mice. These results suggest that the expression of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 and PD-L may provide a promising strategy for specific tumor immunotherapy.

1 March 2001 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
YLYvette Latchman
Yvette Latchman
CWClive R. Wood
Clive R. Wood
TCTatyana Chernova
Tatyana Chernova
DCDivya Chaudhary
Divya Chaudhary
MBMadhuri Borde
Madhuri Borde
GFGordon J. Freeman
Gordon J. Freeman

12 January 2001 in Science
Verified
Journal Article
Closed access
PDF file
HNHiroyuki Nishimura
Hiroyuki Nishimura
TOTaku Okazaki
Taku Okazaki
Yoshimasa TanakaYoshimasa Tanaka
Yoshimasa Tanaka
KNKazuki Nakatani
Kazuki Nakatani
MHMasatake Hara
Masatake Hara
THTasuku Honjo
Tasuku Honjo
Dilated cardiomyopathy is a severe pathology of the heart with poorly understood etiology. Disruption of the gene encoding the negative immunoregulatory receptor PD-1 in BALB/c mice, but not in BALB/c RAG-2 −/− mice, caused dilated cardiomyopathy with severely impaired contraction and sudden death by congestive heart failure. Affected hearts showed diffuse deposition of immunoglobulin G (IgG) on the surface of cardiomyocytes. All of the affected PD-1 −/− mice exhibited high-titer circulating IgG autoantibodies reactive to a 33-kilodalton protein expressed specifically on the surface of cardiomyocytes. These results indicate that PD-1 may be an important factor contributing to the prevention of autoimmune diseases.

27 February 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JHJunzo Hamanishi
Junzo Hamanishi
MMMasaki Mandai
Masaki Mandai
MIMasashi Iwasaki
Masashi Iwasaki
TOTaku Okazaki
Taku Okazaki
Yoshimasa TanakaYoshimasa Tanaka
Yoshimasa Tanaka
SFShingo Fujii
Shingo Fujii
The ligands for programmed cell death 1 (PD-1), an immunoinhibitory receptor belonging to CD28/cytotoxic T lymphocyte antigen 4 family, are PD-1 ligand 1 and 2 (PD-Ls). Recent reports suggest that the aberrant expression of PD-Ls on tumor cells impairs antitumor immunity, resulting in the immune evasion of the tumor cells. Although an inverse correlation between the expression level of PD-Ls and patients' prognosis has been reported for several malignant tumors, the follow-up period was limited because of the lack of the antibody (Ab) applicable to paraffin-embedded specimens. Here we generated a new Ab against PD-1 ligand 1 (PD-L1) and analyzed the expression level of PD-Ls in human ovarian cancer using paraffin-embedded specimens. Patients with higher expression of PD-L1 had a significantly poorer prognosis than patients with lower expression. Although patients with higher expression of PD-1 ligand 2 also had a poorer prognosis, the difference was not statistically significant. A significant inverse correlation was observed between PD-L1 expression and the intraepithelial CD8+T lymphocyte count, suggesting that PD-L1 on tumor cells directly suppresses antitumor CD8+T cells. Multivariate analysis showed the expression of PD-L1 on tumor cells and intraepithelial CD8+T lymphocyte count are independent prognostic factors. The PD-1/PD-L pathway can be a good target for restoring antitumor immunity in ovarian cancer.

15 November 2013 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TOTaku Okazaki
Taku Okazaki
SCShunsuke Chikuma
Shunsuke Chikuma
YIYoshiko Iwai
Yoshiko Iwai
SFSidonia Fagarasan
Sidonia Fagarasan
THTasuku Honjo
Tasuku Honjo
PD-1, a negative coreceptor expressed on antigen-stimulated T cells and B cells, seems to serve as a 'rheostat' of the immune response. The molecular mechanisms of the functions of PD-1, in conjunction with the mild, chronic and strain-specific autoimmune phenotypes of PD-1-deficient mice, in contrast to the devastating fatal autoimmune disease of mice deficient in the immunomodulatory receptor CTLA-4, suggest that immunoregulation by PD-1 is rather antigen specific and is mainly cell intrinsic. Such unique properties make PD-1 a powerful target for immunological therapy, with highly effective clinical applications for cancer treatment.